CA3049624A1 - Probiotic compositions and uses thereof - Google Patents
Probiotic compositions and uses thereof Download PDFInfo
- Publication number
- CA3049624A1 CA3049624A1 CA3049624A CA3049624A CA3049624A1 CA 3049624 A1 CA3049624 A1 CA 3049624A1 CA 3049624 A CA3049624 A CA 3049624A CA 3049624 A CA3049624 A CA 3049624A CA 3049624 A1 CA3049624 A1 CA 3049624A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- lactobacillus
- mean
- probiotic
- placebo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 61
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 61
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 208000015943 Coeliac disease Diseases 0.000 claims abstract description 90
- 241000186660 Lactobacillus Species 0.000 claims abstract description 62
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 23
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 23
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 20
- 230000005784 autoimmunity Effects 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 19
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 claims description 17
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims description 17
- 230000001900 immune effect Effects 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 230000000405 serological effect Effects 0.000 claims description 6
- 230000002085 persistent effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108010047762 HLA-DQ8 antigen Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011785 micronutrient Substances 0.000 claims description 2
- 235000013369 micronutrients Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 68
- 239000000902 placebo Substances 0.000 description 68
- 229940068196 placebo Drugs 0.000 description 68
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 32
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 32
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 32
- 210000004698 lymphocyte Anatomy 0.000 description 29
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 23
- 108010004729 Phycoerythrin Proteins 0.000 description 22
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 21
- 102100033467 L-selectin Human genes 0.000 description 20
- 210000002443 helper t lymphocyte Anatomy 0.000 description 17
- 230000007423 decrease Effects 0.000 description 14
- 102000054766 genetic haplotypes Human genes 0.000 description 14
- 235000006171 gluten free diet Nutrition 0.000 description 13
- 235000020884 gluten-free diet Nutrition 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000000822 natural killer cell Anatomy 0.000 description 11
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 9
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 9
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 8
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 8
- 108010061711 Gliadin Proteins 0.000 description 8
- 108010068370 Glutens Proteins 0.000 description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 235000021312 gluten Nutrition 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000008823 permeabilization Effects 0.000 description 5
- 238000003653 radioligand binding assay Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- HZWWPUTXBJEENE-UHFFFAOYSA-N 5-amino-2-[[1-[5-amino-2-[[1-[2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound C1CCC(C(=O)NC(CCC(N)=O)C(=O)N2C(CCC2)C(=O)NC(CCC(N)=O)C(O)=O)N1C(=O)C(N)CC1=CC=C(O)C=C1 HZWWPUTXBJEENE-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 206010061291 Mineral deficiency Diseases 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229960003284 iron Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 235000016804 zinc Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000007414 peripheral immune response Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100495352 Candida albicans CDR4 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102210047476 DQA1*02:01 Human genes 0.000 description 1
- 102210047285 DQA1*05:01 Human genes 0.000 description 1
- 102210047212 DQB1*02:02 Human genes 0.000 description 1
- 102210047287 DQB1*03:02 Human genes 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- -1 IFN-y Proteins 0.000 description 1
- 208000007924 IgA Deficiency Diseases 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020801 mineral status Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 235000020812 vitamin status Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1700542.2 | 2017-01-12 | ||
| GBGB1700542.2A GB201700542D0 (en) | 2017-01-12 | 2017-01-12 | Probiotic compositions and uses thereof |
| GBGB1709731.2A GB201709731D0 (en) | 2017-06-19 | 2017-06-19 | Probiotic compositions and uses thereof |
| GB1709731.2 | 2017-06-19 | ||
| PCT/EP2018/050789 WO2018130667A1 (en) | 2017-01-12 | 2018-01-12 | Probiotic compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3049624A1 true CA3049624A1 (en) | 2018-07-19 |
Family
ID=61386800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3049624A Pending CA3049624A1 (en) | 2017-01-12 | 2018-01-12 | Probiotic compositions and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11166993B2 (enExample) |
| EP (1) | EP3568144B1 (enExample) |
| JP (1) | JP7089523B2 (enExample) |
| KR (1) | KR102500496B1 (enExample) |
| CN (1) | CN110177561B (enExample) |
| AU (1) | AU2018207946B2 (enExample) |
| BR (1) | BR112019014418A2 (enExample) |
| CA (1) | CA3049624A1 (enExample) |
| CL (1) | CL2019001938A1 (enExample) |
| MX (1) | MX2019008292A (enExample) |
| MY (1) | MY195253A (enExample) |
| PH (1) | PH12019501629A1 (enExample) |
| RU (1) | RU2763311C2 (enExample) |
| WO (1) | WO2018130667A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013439A (es) * | 2018-06-18 | 2021-05-12 | Probi Ab | Composiciones probioticas y usos de las mismas. |
| IT201900014550A1 (it) * | 2019-08-09 | 2021-02-09 | Abiogen Pharma Spa | Uso di colecalciferolo come agente attivo nel trattamento della celiachia |
| CN116869141A (zh) * | 2022-05-05 | 2023-10-13 | 内蒙古一康健康发展有限责任公司 | 一种具有保健功能的益生菌复合物及其制备方法 |
| KR102845919B1 (ko) * | 2023-02-28 | 2025-08-14 | 주식회사 피엘비앤비 | 장내 유해세균의 성장 억제 성능이 우수한 한국인 모유 유래 락티카제이바실러스 파라카제이 pl1536 및 이를 유효성분으로 포함하는 기능성식품 조성물 |
| CN119279210A (zh) * | 2024-12-16 | 2025-01-10 | 山东健源生物科技有限公司 | 一种复合益生菌发酵含药食同源物质的多谷物后生元制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076615A2 (en) * | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
| WO2006097949A1 (en) * | 2005-03-16 | 2006-09-21 | Actial Farmacêutica, Lda. | Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough |
| ZA200802934B (en) * | 2005-10-06 | 2009-09-30 | Probi Ab | Use of lactobacillus for treatment of virus infections |
| EP1951273B1 (en) | 2005-10-06 | 2014-02-12 | Probi Ab | Use of lactobacillus for treatment of autoimmune diseases |
| PL1996696T3 (pl) | 2006-03-17 | 2017-08-31 | Probi Aktiebolag | Termostabilne szczepy Lactobacillus |
| WO2007108763A1 (en) * | 2006-03-17 | 2007-09-27 | Probac Ab | Use of lactobacillus strains for promoting immunotolerance in autoimmune disease |
| PT2367561E (pt) | 2008-11-30 | 2015-10-23 | Immusant Inc | Composições e métodos para o tratamento da doença celíaca |
| EP2581461B1 (en) * | 2011-10-14 | 2014-09-24 | GenMont Biotech Incorporation | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases |
| RU2654705C2 (ru) * | 2012-06-18 | 2018-05-22 | Г.Дж. Хайнц Компани Брэндс ЛЛК | Глютенозависимые расстройства |
| AU2014250113B2 (en) * | 2013-04-03 | 2017-03-30 | Probi Ab | Probiotic strains for use in treatment or prevention of osteoporosis |
| WO2016083450A2 (en) * | 2014-11-25 | 2016-06-02 | Stichting Top Institute Food And Nutrition | New probiotic and new biomarker |
-
2018
- 2018-01-12 WO PCT/EP2018/050789 patent/WO2018130667A1/en not_active Ceased
- 2018-01-12 EP EP18707627.8A patent/EP3568144B1/en active Active
- 2018-01-12 US US16/477,259 patent/US11166993B2/en active Active
- 2018-01-12 CN CN201880006818.0A patent/CN110177561B/zh active Active
- 2018-01-12 RU RU2019121145A patent/RU2763311C2/ru active
- 2018-01-12 AU AU2018207946A patent/AU2018207946B2/en active Active
- 2018-01-12 MY MYPI2019003890A patent/MY195253A/en unknown
- 2018-01-12 KR KR1020197022803A patent/KR102500496B1/ko active Active
- 2018-01-12 BR BR112019014418A patent/BR112019014418A2/pt unknown
- 2018-01-12 JP JP2019538207A patent/JP7089523B2/ja active Active
- 2018-01-12 MX MX2019008292A patent/MX2019008292A/es unknown
- 2018-01-12 CA CA3049624A patent/CA3049624A1/en active Pending
-
2019
- 2019-07-11 CL CL2019001938A patent/CL2019001938A1/es unknown
- 2019-07-12 PH PH12019501629A patent/PH12019501629A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3568144C0 (en) | 2024-05-08 |
| EP3568144A1 (en) | 2019-11-20 |
| MY195253A (en) | 2023-01-11 |
| US11166993B2 (en) | 2021-11-09 |
| CN110177561B (zh) | 2023-09-12 |
| CL2019001938A1 (es) | 2019-09-27 |
| AU2018207946A1 (en) | 2019-07-25 |
| PH12019501629A1 (en) | 2020-06-01 |
| KR102500496B1 (ko) | 2023-02-16 |
| RU2763311C2 (ru) | 2021-12-28 |
| EP3568144B1 (en) | 2024-05-08 |
| US20190358275A1 (en) | 2019-11-28 |
| AU2018207946B2 (en) | 2024-07-18 |
| RU2019121145A (ru) | 2021-02-12 |
| MX2019008292A (es) | 2019-09-16 |
| CN110177561A (zh) | 2019-08-27 |
| RU2019121145A3 (enExample) | 2021-04-26 |
| BR112019014418A2 (pt) | 2020-04-14 |
| JP7089523B2 (ja) | 2022-06-22 |
| WO2018130667A1 (en) | 2018-07-19 |
| JP2020513780A (ja) | 2020-05-21 |
| KR20190104568A (ko) | 2019-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018207946B2 (en) | Probiotic compositions and uses thereof | |
| Miyazawa et al. | Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study | |
| Cook et al. | Circulating gluten-specific FOXP3+ CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease | |
| Hornsby et al. | Vitamin D supplementation during pregnancy: effect on the neonatal immune system in a randomized controlled trial | |
| DK1951272T3 (en) | Use of lactobacillus for treatment of virus infections | |
| Hu et al. | Maternal antibiotic treatment protects offspring from diabetes development in nonobese diabetic mice by generation of tolerogenic APCs | |
| EP3539548B1 (en) | Composition for inducing proliferation or accumulation of regulatory cells | |
| Hardy et al. | Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease | |
| EP3310367A1 (en) | Induction of lamina propria regulatory t cells | |
| Kim et al. | Identification of atopic dermatitis phenotypes with good responses to probiotics (Lactobacillus plantarum CJLP133) in children | |
| Sredkova et al. | Prebiotics can change immunomodulatory properties of probiotics | |
| US11590181B2 (en) | Serpin production | |
| US20160139123A1 (en) | Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid | |
| Dons’koi et al. | HCMV seropositivity is associated with specific proinflammatory immune phenotype in women with implantation failure | |
| Huang et al. | Propionic fermentation by the probiotic Propionibacterium freudenreichii to functionalize whey | |
| Enomoto et al. | Oral administration of Lactobacillus plantarum NRIC0380 suppresses IgE production and induces CD4+ CD25+ Foxp3+ cells in vivo | |
| Talayev et al. | Cytokine profile of CCR6+ T-helpers isolated from the blood of patients with peptic ulcer associated with Helicobacter pylori infection | |
| Nehra et al. | Celiac disease and its therapy: current approaches and new advances | |
| Noorifard et al. | Effects of probiotic supplementation on immune response in soldiers: a randomized, double-blinded, placebo-controlled trial | |
| Motkowski et al. | Peripheral blood T lymphocyte subsets in children with congenital asplenia | |
| Sánchez et al. | Effect of maize prolamins on peripheral blood mononuclear cells from celiac disease patients | |
| Hungerford | Coeliac disease | |
| Hrdý | Immunologic Characteristics of Cord Blood in Children with Increased Risk of Allergy Development Preventive Use of Probiotics | |
| Lahcene et al. | Characterization of intestinal microbiota in celiac children | |
| Pozo-Rubio et al. | Pozo-Rubio T et al. Br J Nutr. 2011 Oct; 106 (8): 1216-23 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230106 |
|
| EEER | Examination request |
Effective date: 20230106 |
|
| EEER | Examination request |
Effective date: 20230106 |